These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 1756248

  • 1. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
    Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF.
    Int J Hematol; 1991 Oct; 54(5):371-5. PubMed ID: 1756248
    [Abstract] [Full Text] [Related]

  • 2. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M, Maschio M, Trua G, Papa G.
    Haematologica; 1991 Oct; 76(2):131-4. PubMed ID: 1937171
    [Abstract] [Full Text] [Related]

  • 3. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T, Ferro G, Frontini V, Percolla S.
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [Abstract] [Full Text] [Related]

  • 4. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 Jan; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 5. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 6. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
    Krüger N, Ullrich D, Tillmann W, Schröter W.
    Dtsch Med Wochenschr; 1985 Nov 29; 110(48):1848-51. PubMed ID: 4064938
    [Abstract] [Full Text] [Related]

  • 7. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr 29; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 8. Effects of deferoxamine on renal function in thalassemia.
    Hyman CB, Gonick HC, Agness C, Nadorra R, Landing B.
    Birth Defects Orig Artic Ser; 1988 Apr 29; 23(5B):135-40. PubMed ID: 3390536
    [No Abstract] [Full Text] [Related]

  • 9. Urinary zinc excretion and zinc status of patients with beta-thalassemia major.
    Aydinok Y, Coker C, Kavakli K, Polat A, Nisli G, Cetiner N, Kantar M, Cetingül N.
    Biol Trace Elem Res; 1999 Nov 29; 70(2):165-72. PubMed ID: 10535525
    [Abstract] [Full Text] [Related]

  • 10. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS, Sanchis de Herrlein MS, Peñalver JA.
    Medicina (B Aires); 1985 Nov 29; 45(3):231-4. PubMed ID: 3841934
    [No Abstract] [Full Text] [Related]

  • 11. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
    Baath JS, Lam WC, Kirby M, Chun A.
    Retina; 2008 Jun 29; 28(6):894-9. PubMed ID: 18536609
    [Abstract] [Full Text] [Related]

  • 12. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H, Goshen J, Carmi D, Yaniv I, Kaplinsky C, Cohen IJ, Zaizov R.
    Isr J Med Sci; 1994 Aug 29; 30(8):658-64. PubMed ID: 8045754
    [Abstract] [Full Text] [Related]

  • 13. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct 29; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 14. [Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
    Krüger N, Stubbe P, Tillmann W, Schröter W.
    Dtsch Med Wochenschr; 1986 May 02; 111(18):698-701. PubMed ID: 3486106
    [Abstract] [Full Text] [Related]

  • 15. Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment.
    Miralbell R, Sancho G, Bieri S, Carrió I, Helg C, Brunet S, Martin PY, Sureda A, Gomez De Segura G, Chapuis B, Estorch M, Ozsahin M, Keller A.
    Int J Radiat Oncol Biol Phys; 2004 Mar 01; 58(3):809-16. PubMed ID: 14967438
    [Abstract] [Full Text] [Related]

  • 16. [Longitudinal growth of patients with homozygote beta-thalassemia during continuous subcutaneous infusion of deferoxamine].
    Krüger N, Stubbe P, Tillmann W, Schröter W.
    Dtsch Med Wochenschr; 1986 Jan 31; 111(5):176-81. PubMed ID: 3943469
    [Abstract] [Full Text] [Related]

  • 17. [Ocular findings in Desferal therapy].
    Dennerlein JA, Lang GE, Stahnke K, Kleihauer E, Lang GK.
    Ophthalmologe; 1995 Feb 31; 92(1):38-42. PubMed ID: 7719074
    [Abstract] [Full Text] [Related]

  • 18. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 Feb 31; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 19. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB, de Veber LL, Sulh HM.
    Can J Ophthalmol; 1985 Jun 31; 20(4):153-6. PubMed ID: 4052864
    [Abstract] [Full Text] [Related]

  • 20. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung EB, Calvelli L, Quirolo K, Foote D, Harmatz P, Vichinsky EP.
    Ann N Y Acad Sci; 2005 Jun 31; 1054():486-91. PubMed ID: 16339703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.